{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:57:06Z","timestamp":1790575026786,"version":"4.1.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82260598"],"award-info":[{"award-number":["82260598"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the efficacy and safety of neoadjuvant RC-48 combined with a PD-1 inhibitor in patients with muscle-invasive bladder cancer (MIBC), and to investigate the stratification utility of HER2 expression and tumor-associated tertiary lymphoid structures (TLS) as predictive variables for treatment response and clinical prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>This multicenter retrospective real-world study enrolled 38 patients with MIBC from the First Affiliated Hospital of Nanchang University, the Second Affiliated Hospital of Nanchang University, Jiangxi Cancer Hospital, and Jiangxi Provincial People\u2019s Hospital. All patients received at least four cycles of neoadjuvant therapy comprising RC-48 combined with a PD-1 inhibitor, followed by radical cystectomy (RC). The TLS in the pre-treatment specimens was evaluated using hematoxylin-eosin (HE) staining, and the expression level of HER2 was assessed by immunohistochemistry (IHC) method. The primary endpoint was the pathological complete response (pCR) rate, and secondary endpoints included radiographic complete response (CR) rate, disease-free survival (DFS), and overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 38 patients, the pCR rate was 34.2%, and the overall CR rate by radiographic assessment was 36.8%, with a PR rate of 31.6%. After a median follow-up of 18.0 months (range, 9\u201329 months), the 12-month DFS rate was 89.4% (95% CI: 74.2%\u201395.9%), and the 12-month OS rate was 100% (95% CI: 100%\u2013100%). HER2 overexpression was significantly associated with a higher objective response rate (ORR) (OR\u00a0=\u00a022.50, 95% CI: 1.51 - 335.33, p = 0.024). In stratified analyses based on TLS, both TLS-2 (primary lymphoid follicles) and TLS-3 (secondary lymphoid follicles with germinal centers) demonstrated significant associations with higher ORR, with ORs of 20.00 (95% CI: 2.75 - 145.48, p = 0.003) and 36.00 (95% CI: 2.72 - 476.21, p = 0.007), respectively, suggesting that greater TLS with enhanced therapeutic benefit. Furthermore, N1 stage (OR\u00a0=\u00a00.06, 95% CI: 0.01 - 0.59, p = 0.016), N2 stage (OR\u00a0=\u00a00.04, 95% CI: 0.00 - 0.62, p = 0.021), and T3 stage (OR\u00a0=\u00a00.08, 95% CI: 0.01 - 0.46, p = 0.004) were each significantly associated with poorer treatment response. Treatment-related adverse events (TRAEs) were generally manageable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The combination of RC-48 and a PD-1 inhibitor exhibits promising efficacy as a neoadjuvant therapy for MIBC. Both HER2 expression and TLS maturity serve as effective stratification indicators for treatment response and prognosis. These findings support further evaluation of this combined regimen in biomarker-driven prospective trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1891151","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:44:00Z","timestamp":1790574240000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant disitamab vedotin (RC-48) plus a PD-1 inhibitor in muscle-invasive bladder cancer: a multicenter real-world study with stratification by HER2 expression and tertiary lymphoid structures"],"prefix":"10.3389","volume":"17","author":[{"given":"Xue Peng","family":"Rao","sequence":"first","affiliation":[{"name":"Department of Urology, Second Affiliated Hospital of Nanchang University, Jiangxi Medical College","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin Chang","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Urology, Second Affiliated Hospital of Nanchang University, Jiangxi Medical College","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Urology, Second Affiliated Hospital of Nanchang University, Jiangxi Medical College","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lie Yu","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Urology, Jiangxi Provincial People\u2019s Hospital","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian Biao","family":"Huang","sequence":"additional","affiliation":[{"name":"Jiangxi Cancer Hospital & Institute, Jiangxi Clinical Research Center for Cancer, The Second Affiliated Hospital of Nanchang Medical College","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Yang","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Urology, First Affiliated Hospital of Nanchang University","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Urology, Second Affiliated Hospital of Nanchang University, Jiangxi Medical College","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Urology, Second Affiliated Hospital of Nanchang University, Jiangxi Medical College","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.03.029","article-title":"Epidemiology of bladder cancer in 2023: A systematic review of risk factors","volume":"84","author":"Jubber","year":"2023","journal-title":"Eur Urol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2020 guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur Urol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2023.2281654","article-title":"Three versus four cycles of neoadjuvant chemotherapy for muscle-invasive bladder cancer: A systematic review and meta-analysis","volume":"55","author":"Wang","year":"2023","journal-title":"Ann Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103795","article-title":"Neoadjuvant therapy for muscle-invasive bladder cancer: Current clinical scenario, future perspectives, and unsolved questions","volume":"178","author":"Ruiz de Porras","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22137201","article-title":"Perioperative systemic treatment for muscle-invasive bladder cancer: Current evidence and future perspectives","volume":"22","author":"Kim","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-024-15725-8","article-title":"Recent advances of neoadjuvant immunotherapy for urothelial bladder cancer","volume":"31","author":"Zhang","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.04.013","article-title":"Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder","volume":"82","author":"Szabados","year":"2022","journal-title":"Eur Urol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2020.06.009","article-title":"Rationale and outcomes for neoadjuvant immunotherapy in urothelial carcinoma of the bladder","volume":"3","author":"Rouanne","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2025.102408","article-title":"Neoadjuvant PD-1\/PD-L1 inhibitors for muscle-invasive bladder cancer: A meta-analysis","volume":"23","author":"Hu","year":"2025","journal-title":"Clin Genitourin Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1332213","article-title":"Efficacy and safety of neoadjuvant PD-1 inhibitors or PD-L1 inhibitors for muscle invasive bladder cancer: A systematic review and meta-analysis","volume":"14","author":"Huang","year":"2024","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.986359","article-title":"Neoadjuvant immunotherapy and chemoimmunotherapy for stage II-III muscle invasive bladder cancer","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-01211-1","article-title":"Disitamab vedotin (RC48-ADC) combined with immunotherapy as neoadjuvant therapy for localized muscle-invasive bladder cancer: A multicenter real-world study","volume":"10","author":"Guo","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011881","article-title":"Overcoming immunotherapy resistance in bladder cancer with a novel antibody-drug conjugate RC48","volume":"13","author":"Xiao","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s10549-021-06384-4","article-title":"A HER2 target antibody drug conjugate combined with anti-PD-(L)1 treatment eliminates hHER2+\u2009tumors in hPD-1 transgenic mouse model and contributes immune memory formation","volume":"191","author":"Huang","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.12.002","article-title":"Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): A phase Ib\/II dose-escalation and dose-expansion study","volume":"36","author":"Zhou","year":"2025","journal-title":"Ann Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1233196","article-title":"RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2-positive locally advanced muscle-invasive urothelial bladder cancer: A multi-center phase Ib\/II study (HOPE-03)","volume":"13","author":"Wen","year":"2024","journal-title":"Front Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076743","article-title":"Advances in diagnosis and treatment of bladder cancer","volume":"384","author":"Lopez-Beltran","year":"2024","journal-title":"BMJ"},{"key":"B18","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-023-00468-9","article-title":"Bladder cancer","volume":"9","author":"Dyrskj\u00f8t","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"B19","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.85071","article-title":"A comparative study of gemcitabine-cisplatin vs. dose-dense MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin) as neoadjuvant chemotherapy for muscle-invasive bladder cancer: A single-institution experience","volume":"17","author":"Goel","year":"2025","journal-title":"Cureus"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-024-00822-0","article-title":"Neoadjuvant gemcitabine-cisplatin plus tislelizumab in persons with resectable muscle-invasive bladder cancer: A multicenter, single-arm, phase 2 trial","volume":"5","author":"Li","year":"2024","journal-title":"Nat Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4111\/icu.20230006","article-title":"Perioperative systemic therapy in muscle invasive bladder cancer: Current standard method, biomarkers and emerging strategies","volume":"64","author":"Kim","year":"2023","journal-title":"Investig Clin Urol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2020.1784011","article-title":"Neoadjuvant therapy for muscle-invasive bladder cancer","volume":"20","author":"Jain","year":"2020","journal-title":"Expert Rev Anticancer Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2022.2069883","article-title":"Disitamab vedotin: A novel antibody-drug conjugates for cancer therapy","volume":"29","author":"Shi","year":"2022","journal-title":"Drug Delivery"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1177\/17562872241249073","article-title":"Systematic review of recent advancements in antibody-drug and bicycle toxin conjugates for the treatment of urothelial cancer","volume":"16","author":"Domb","year":"2024","journal-title":"Ther Adv Urol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02912","article-title":"Efficacy and safety of disitamab vedotin in patients with human epidermal growth factor receptor 2-positive locally advanced or metastatic urothelial carcinoma: A combined analysis of two phase II clinical trials","volume":"42","author":"Sheng","year":"2024","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1080\/1750743X.2025.2501929","article-title":"Neoadjuvant immunotherapy for muscle-invasive bladder cancer: A 2025 update","volume":"17","author":"Giannakodimos","year":"2025","journal-title":"Immunotherapy"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01148","article-title":"Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): An open-label, single-arm, phase II study","volume":"36","author":"Necchi","year":"2018","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0628-7","article-title":"Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial","volume":"25","author":"Powles","year":"2019","journal-title":"Nat Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/abt\/tbaf017","article-title":"Reprogramming the tumor microenvironment: Synergistic mechanisms of antibody-drug conjugates and immune checkpoint inhibitors","volume":"8","author":"Yin","year":"2025","journal-title":"Antib Ther"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2025.101216","article-title":"Disitamab vedotin combined with toripalimab and radiotherapy for multimodal organ-sparing treatment of muscle invasive bladder cancer: A proof-of-concept study","volume":"68","author":"Zhang","year":"2025","journal-title":"Neoplasia"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70978","article-title":"Tertiary lymphoid structures as independent predictors of favorable prognosis in muscle-invasive bladder cancer","volume":"14","author":"Teng","year":"2025","journal-title":"Cancer Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1186\/s12885-026-16326-2","article-title":"The predictive role of tertiary lymphoid structures in the prognosis and response to immunotherapy of bladder cancer patients: A systematic review and meta-analysis","volume":"26","author":"Hu","year":"2026","journal-title":"BMC Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-022-04160-7","article-title":"Multicenter evaluation of neoadjuvant and induction gemcitabine-carboplatin versus gemcitabine-cisplatin followed by radical cystectomy for muscle-invasive bladder cancer","volume":"40","author":"Einerhand","year":"2022","journal-title":"World J Urol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1891151\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:44:01Z","timestamp":1790574241000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1891151\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":34,"alternative-id":["10.3389\/fimmu.2026.1891151"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1891151","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"article-number":"1891151"}}